Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
With an IC50 of 3.3 mg/L, mycophenolic acid glucuronide exhibits a modest type II inhibition of IMP dehydrogenase (IMPDH)[3].
|
---|---|
ln Vivo |
In an Ehrlich murine spontaneous adenocarcinoma model, mycophenolic acid glucuronide (intraperitoneal injection; 6 mg/mouse; once two days; 6 d) therapy inhibits tumor growth[2].
|
Animal Protocol |
Animal/Disease Models: Swiss albino strain mouse implanted with Ehrlich ascites tumor cells[2]
Doses: 6 mg/mouse Route of Administration: intraperitoneal (ip) injection; 6 mg/mouse; once two days; 6 d Experimental Results: demonstrated 76.8% tumor inhibition compared to the untreated control. |
References |
[1]. Natascha A Wolff, et al. Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transplant. 2007 Sep;22(9):2497-503.
[2]. Ando K, et al. Synthesis of mycophenolic acid beta-D-glucuronide and its antitumor activity. J Antibiot (Tokyo). 1970 Aug;23(8):408-13. [3]. Gensburger O, et al. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin Chem. 2009 May;55(5):986-93. |
Molecular Formula |
C23H28O12
|
---|---|
Molecular Weight |
496.46
|
CAS # |
31528-44-6
|
Related CAS # |
Mycophenolic acid glucuronide-d3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C/C(=C\CC1=C(C2=C(COC2=O)C(=C1OC)C)OC3C(C(C(C(C(=O)O)O3)O)O)O)/CCC(=O)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 33.33 mg/mL (67.14 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0143 mL | 10.0713 mL | 20.1426 mL | |
5 mM | 0.4029 mL | 2.0143 mL | 4.0285 mL | |
10 mM | 0.2014 mL | 1.0071 mL | 2.0143 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.